Aridis Pharmaceuticals, Inc’s AR-301 has failed a pivotal ventilator-associated pneumonia (VAP) trial due to problems with patient enrolment but analysts are optimistic about what the data could mean for a second planned Phase III trial.
The Phase III AR-301-002 trial evaluated AR-301 as an adjunctive treatment with standard-of-care antibiotics for VAP caused by Staphylococcus aureus infection
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?